Why is AYR Wellness (OTCQX: AYRWF) losing its interim CFO now—and what does that signal to investors?

AYR Wellness Inc. (OTCQX: AYRWF) has announced that interim Chief Financial Officer Donna Granato will exit the company effective December 31, 2025, following a nine-month tenure. The leadership update comes as AYR Wellness proceeds with a broader restructuring process, including asset divestitures, corporate simplification, and executive realignment aimed at navigating a distressed capital and regulatory environment in the U.S. cannabis sector.

Granato’s departure was framed by the company as aligned with its transitional strategy and long-planned wind-down of the legacy corporate structure. However, the loss of a seasoned finance head during a high-leverage operational reset could signal deeper concerns around execution risk and stakeholder confidence.

What role did Donna Granato play during AYR Wellness’s debt restructuring and how significant was her short tenure?

Donna Granato joined AYR Wellness in March 2025 as interim CFO during one of the company’s most volatile financial periods. Her background included CFO-level roles at Vivvix and GTT Communications, as well as leadership positions at Shutterstock, Tribune Media, and Omnicom Group—bringing multi-industry experience to a cannabis firm struggling with sector-wide cash flow compression.

Over her nine months at AYR Wellness, Granato’s mandate spanned cost optimization, cash preservation, and executing capital structure workarounds under increasingly constrained access to credit. She played a key role in facilitating an orderly wind-down plan for the holding company, supporting the financial groundwork for asset transfers and entity simplifications.

According to interim CEO Blake Holzgrafe, Granato “provided steady leadership during a critical time,” suggesting her exit was not abrupt, but a milestone tied to a transition roadmap. Still, her tenure was notably brief, and the company has not yet announced a successor CFO.

How does the CFO exit fit into AYR’s broader corporate wind-down and what execution risks remain?

AYR Wellness has been systematically unwinding its prior structure, a move it described in earlier filings as necessary to facilitate go-forward operations under a more sustainable asset-light model. This includes shedding underperforming or non-core licenses, rightsizing its geographic footprint, and preparing specific state-level operations for divestiture or consolidation.

The transition is reportedly being managed with an emphasis on maximizing value recovery for creditors and preserving operational continuity in remaining state markets. However, such restructurings are rarely clean, and CFO transitions during this phase tend to raise concerns over internal control consistency, reporting stability, and refinancing continuity—especially in cannabis, where federal illegality continues to limit traditional bankruptcy protections or lender appetite.

Granato’s exit leaves a temporary vacuum in financial stewardship at a time when stakeholder alignment and intercreditor negotiations require strong institutional memory. That increases execution risk during this liminal phase, particularly if key financial leadership roles remain unfilled.

How are markets reacting to the CFO departure and what is investor sentiment around AYR Wellness?

AYR Wellness shares, traded on the OTCQX under ticker AYRWF, saw a sharp intraday decline following the leadership announcement, underscoring investor unease around continued instability at the top. Although the stock has experienced prolonged drawdowns amid sector-wide headwinds, the latest development compounds concerns that the company may be approaching the limits of its restructuring capacity without clearer visibility on future governance and liquidity access.

Analysts and retail investors have shown caution in their outlooks. The company’s legacy debt burden, margin pressures, and limited access to conventional refinancing windows have kept sentiment muted. Even positive signals like cost reductions or regional sales stabilization have failed to spark a sustained recovery in valuation. Granato’s exit is thus seen less as an individual event and more as another variable in a pattern of strategic volatility.

In the absence of a clear successor or updated financial leadership plan, market participants may assume additional turnover or instability is forthcoming—especially if other senior executives follow suit.

How does AYR’s leadership transition compare to peers in the U.S. cannabis sector?

AYR Wellness is not alone in undergoing executive churn amid financial distress. Other multi-state operators (MSOs) such as MedMen, Tilt Holdings, and iAnthus have all experienced senior leadership changes in the past 12–18 months as their debt profiles, cost structures, and regulatory friction points collided with investor expectations.

Unlike larger players like Curaleaf Holdings or Trulieve Cannabis Corporation, AYR Wellness lacks scale-driven insulation or strong institutional equity support, making its turnaround efforts more fragile. Smaller MSOs have typically opted for interim leadership or external restructuring consultants as they negotiate asset sales or pursue reverse merger scenarios.

That puts pressure on AYR Wellness to communicate succession plans clearly and quickly. Without a replacement CFO and given that its current CEO is also in an interim capacity, the company risks falling into what analysts describe as a “two-interim trap”—where strategic continuity is compromised and external confidence wanes further.

What happens next for AYR Wellness and what should institutional investors be watching?

AYR Wellness will need to demonstrate that its leadership reset is part of a deliberate and staged plan rather than a reactive series of departures. That means articulating a CFO succession roadmap, offering more transparency on asset transfer progress, and outlining governance priorities as it pivots toward a simplified, post-wind-down entity structure.

Additionally, the company must reassure investors that liquidity remains under control and that operational state-level units are not at risk of service disruption. With broader sector M&A largely frozen and institutional capital retreating from cannabis debt in the wake of successive write-downs, AYR’s best path forward may involve a white-label licensing pivot or a slimmed-down regional play with low operating overheads.

For now, Donna Granato’s exit leaves a conspicuous leadership void—and raises questions about whether AYR Wellness can credibly execute its turnaround strategy without strong internal financial continuity.

What the CFO departure from AYR Wellness means for leadership, liquidity, and sector confidence

• Interim CFO Donna Granato will leave AYR Wellness effective December 31, 2025, after nine months in the role.
• Her exit coincides with the company’s broader restructuring and corporate wind-down strategy, signaling possible completion of key financial milestones.
• AYR Wellness has yet to name a successor CFO, adding uncertainty during a high-stakes transitional period for creditors and investors.
• Market reaction was negative, with AYRWF shares falling sharply amid renewed concerns about executive instability and cash flow risk.
• The departure reflects sector-wide leadership turnover among smaller MSOs struggling with limited refinancing options and operational drag.
• Interim CEO Blake Holzgrafe remains in place, but the dual-interim leadership structure raises governance red flags for institutional investors.
• AYR must now clarify its executive roadmap and demonstrate financial discipline to preserve value through its transition.
• Sector peers are watching closely as AYR becomes a test case for whether smaller cannabis firms can reset under capital and regulatory strain.